541 filings
Page 14 of 28
8-K
ozrkf08f0 x9aoi20
18 Apr 19
Entry into a Material Definitive Agreement
5:00pm
8-K
rrdh458 71z
4 Apr 19
Entry into a Material Definitive Agreement
12:00am
424B5
h1a dd3rfa3p
4 Apr 19
Prospectus supplement for primary offering
12:00am
8-K
1lech11p 0tdd5
2 Apr 19
Regulation FD Disclosure
8:15am
8-K
rhawy 9xby37n2x2u5d
28 Mar 19
Heat Biologics Reports 2018 Results and Provides Corporate Update
7:35am
8-A12B/A
225041
13 Mar 19
Registration of securities on exchange (amended)
6:02am
8-K
ilg7yw
12 Mar 19
Entry into a Material Definitive Agreement
8:00am
8-K
zhswxw6v
28 Feb 19
Regulation FD Disclosure
2:37pm
8-K
3uu0j8e3n2
28 Feb 19
Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab at ASCO-SITC Clinical Immuno-Oncology Symposium
12:00am
8-K
wy75tnlwtdwcmo3
25 Feb 19
Other Events
5:01pm
8-K
obb1c2k044s56
14 Jan 19
Other Events
4:30pm
8-K
gte2nii08fjw4
10 Jan 19
Heat Biologics Provides Clinical and Business Update
4:30pm
8-K
gz5 2q18m5
8 Jan 19
Other Events
4:30pm
8-K
jhngjkm9lz
8 Jan 19
Heat Biologics Corporate PresentationJanuary 2019
7:01am
8-K
6ph5n8jioav72nd55efz
3 Jan 19
Departure of Directors or Certain Officers
4:45pm
8-K
d7dupv1vvfm
26 Nov 18
Heat Biologics, Inc. Announces Closing of $13,800,000 Public Offering
5:15pm
8-K
3ar9d 6o3ks3e
21 Nov 18
Heat Biologics, Inc. Announces Proposed Public Offering
4:08pm
424B2
76rh1u7x
21 Nov 18
Prospectus for primary offering
4:06pm
424B5
04vg1ws8b
20 Nov 18
Prospectus supplement for primary offering
5:23pm